Receptors, Tumor Necrosis Factor
"Receptors, Tumor Necrosis Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cell surface receptors that bind TUMOR NECROSIS FACTORS and trigger changes which influence the behavior of cells.
| Descriptor ID |
D018124
|
| MeSH Number(s) |
D12.776.543.750.705.852.760
|
| Concept/Terms |
Receptors, Tumor Necrosis Factor- Receptors, Tumor Necrosis Factor
- Receptors, Cachectin
- Tumor Necrosis Factor Receptors
- TNF Receptor
- Receptor, TNF
- TNF Receptors
- Tumor Necrosis Factor Receptor
- Cachectin Receptors
- Receptors, TNF
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Tumor Necrosis Factor".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Tumor Necrosis Factor".
- Receptors, Tumor Necrosis Factor
- B-Cell Activation Factor Receptor
- B-Cell Maturation Antigen
- CD40 Antigens
- Etanercept
- fas Receptor
- Glucocorticoid-Induced TNFR-Related Protein
- Ki-1 Antigen
- Lymphotoxin beta Receptor
- Receptor Activator of Nuclear Factor-kappa B
- Receptors, Ectodysplasin
- Receptors, OX40
- Receptors, TNF-Related Apoptosis-Inducing Ligand
- Receptors, Tumor Necrosis Factor, Member 14
- Receptors, Tumor Necrosis Factor, Member 25
- Receptors, Tumor Necrosis Factor, Type I
- Receptors, Tumor Necrosis Factor, Type II
- Transmembrane Activator and CAML Interactor Protein
- Tumor Necrosis Factor Decoy Receptors
- Tumor Necrosis Factor Receptor Superfamily, Member 7
- Tumor Necrosis Factor Receptor Superfamily, Member 9
- TWEAK Receptor
This graph shows the total number of publications written about "Receptors, Tumor Necrosis Factor" by people in this website by year, and whether "Receptors, Tumor Necrosis Factor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 0 | 1 |
| 1999 | 1 | 1 | 2 |
| 2000 | 2 | 0 | 2 |
| 2001 | 1 | 3 | 4 |
| 2002 | 4 | 3 | 7 |
| 2003 | 4 | 4 | 8 |
| 2004 | 1 | 2 | 3 |
| 2005 | 4 | 1 | 5 |
| 2006 | 8 | 4 | 12 |
| 2007 | 2 | 4 | 6 |
| 2008 | 0 | 4 | 4 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 2 | 2 | 4 |
| 2013 | 1 | 1 | 2 |
| 2016 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Tumor Necrosis Factor" by people in Profiles.
-
Enhancement of Ovarian Tumor Detection by DR6-Targeted Ultrasound Imaging Agents in Laying Hen Model of Spontaneous Ovarian Cancer. Int J Gynecol Cancer. 2016 10; 26(8):1375-85.
-
Association of Immunosuppression with DR6 Expression during the Development and Progression of Spontaneous Ovarian Cancer in Laying Hen Model. J Immunol Res. 2016; 2016:6729379.
-
Total pancreatectomy with islet autotransplantation: summary of a National Institute of Diabetes and Digestive and Kidney diseases workshop. Pancreas. 2014 Nov; 43(8):1163-71.
-
Synergism between narrowband ultraviolet B phototherapy and etanercept for the treatment of plaque-type psoriasis. Br J Dermatol. 2013 Jul; 169(1):130-6.
-
Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet. 2013 Mar; 9(3):e1003394.
-
A comparison of etanercept vs. infliximab for the treatment of post-arrest myocardial dysfunction in a swine model of ventricular fibrillation. Resuscitation. 2013 Jul; 84(7):999-1003.
-
T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-a) inhibitors: results of the REFURBISH study. Am J Gastroenterol. 2013 Jan; 108(1):99-105.
-
TNF-a and temporal changes in sleep architecture in mice exposed to sleep fragmentation. PLoS One. 2012; 7(9):e45610.
-
Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis. J Am Acad Dermatol. 2012 Aug; 67(2):245-56.
-
Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011 Aug 24; 306(8):864-71.